Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 100 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11418
Sealed predictions
- CST7 in dopamine neurons, braak-0.37 (p 0.334) → -0.07 (p 0.856)receipt 11426
Swarm cases
receipt 11426: CST7 in dopamine neurons, braak
- power
- full sample -0.25 (p 0.310, n 18), 95% CI -0.64 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.25 (p 0.310, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.31 (p 0.214, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.310, n 18). fragile.
- cell type
- strongest in microglia: -0.62 (p 0.0060, n 18) vs -0.25 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CST7 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CST7 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 1.9e-4)
Receipts
loading the receipts